From March 25 to 29, 2024, Zhuhai United Laboratories Co., Ltd. passed a five-day on-site GMP inspection conducted by ANVISA, the official regulatory authority of Brazil. The inspected product varieties included sterile bulk medicines (ceftriaxone sodium, cefotaxime sodium, ampicillin sodium, amoxicillin sodium, clavulanate potassium, sulbactam sodium, amoxicillin sodium and clavulanate potassium 5:1, ampicillin sodium and sulbactam sodium 2:1) and non-sterile bulk medicines (clavulanate potassium, clavulanate potassium and silicon dioxide 1:1).